Labcorp Holdings IncNYSE: LH
Health Care · Health Care Services
$255.80
-1.45%
Vol: 577K
Research Digest
Friday, June 19, 2026
Labcorp launches PD-L1 companion diagnostic for KEYTRUDA in platinum-resistant ovarian cancer and presents at Jefferies Healthcare Conference, with raised FY2026 guidance intact.
Labcorp announced the nationwide rollout of the PD-L1 IHC 22C3 pharmDx companion diagnostic for KEYTRUDA-based treatment in platinum-resistant ovarian cancer, expanding its oncology diagnostics footprint. Management presented at the 2026 Jefferies Global Healthcare Conference on June 3. The company previously reported solid Q1 2026 results with revenue of $3.54 billion (+5.8% YoY) and adjusted EPS of $4.25, accompanied by raised full-year 2026 guidance. A quarterly dividend of $0.72/share was paid June 11, 2026. The stock is currently priced around $265, with analyst models pointing to ~17% upside from current levels. Risk factors include ongoing concerns about declining organic sales, acquisition dependency for growth, and Medicaid reimbursement pressure.
Previous Market Intelligence
13 daysJun 18No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 17No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 16No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 15No significant overnight updatesNeutral▶
No material news in the last 48 hours.
Jun 14No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 21Labcorp expands Epic partnership and launches MyLabcorp AI app while raising FY26 EPS guidancePositive▶
On May 14, Labcorp announced an expanded collaboration with Epic, embedding its full diagnostic test menu into Epic Aura platform to streamline ordering for hospitals. The company also launched MyLabcorp, an AI-powered consumer app combining test results with clinical guidance. Labcorp raised FY26 adjusted EPS guidance to $17.70-$18.35 from $17.55-$18.25, following a Q1 beat with revenue of $3.54B and EPS of $4.25 vs $4.11 estimate. Baird raised its price target to $334 from $332. The risk is concentration on hospital/health-system distribution and competition in the consumer diagnostics app space.
May 20Labcorp raises FY2026 guidance after Q1 beat while CEO sells 5,903 shares and Epic partnership expandsPositive▶
Labcorp announced strong Q1 2026 results with 5.8% revenue growth, 10.6% EPS growth, and margin expansion driven by Diagnostics and Biopharma Laboratory Services strength. The company raised its full-year Adjusted EPS guidance to $18.03 at midpoint, an increase of $0.13. Labcorp and Epic expanded their collaboration on May 12, 2026, deepening data interoperability. On May 11, CEO Adam Schechter sold 5,903 shares while iA Global Asset Management purchased 7,609 shares. Baird raised the price target to $334 from $332 on May 1. The company declared a $0.72 quarterly dividend payable June 11. Stock closed at $255.57 recently, with consensus price target of $311.33 and average Buy rating from 9 analysts.
May 19No significant overnight updatesNeutral▶
No material news in the last 48 hours.
May 18Labcorp expanded Epic partnership on May 14 to embed its full diagnostic test menu into Epic's Aura platform and Baird raised its PT to $334.Positive▶
On May 14, 2026, Labcorp announced an expanded collaboration with Epic, embedding its full diagnostic test menu into Epic's Aura platform to simplify hospital and health system ordering. The company also launched MyLabcorp, an AI-powered mobile app combining test results with clinical guidance. Q1 2026 results showed revenue of $3.54B (up from $3.35B) and diluted EPS of $3.35 vs. $2.52 a year ago, with full-year adjusted EPS guidance raised. Baird raised its price target to $334 (from $332); Evercore ISI reiterated Buy on May 1. LH closed at $255.08 on May 11 with a market cap of $20.92B, with average analyst PT of $310.06.
May 15Labcorp raised FY26 adjusted EPS view to $17.70-$18.35 after Q1 beat, expanded its Epic Aura partnership for diagnostic ordering, and rolled out PD-L1 22C3 companion diagnostic for KEYTRUDA in ovarian cancer.Positive▶
Labcorp Holdings has been on a positive run in early-to-mid May 2026. Q1 2026 revenue rose 7.2% to $3.54B (or $13.95B trailing) with diluted EPS of $3.35 vs $2.52 prior year, and management raised FY26 adjusted EPS guidance to $17.70-$18.35 from $17.55-$18.25. The company expanded its collaboration with Epic, embedding its full diagnostic test menu into Epic's Aura platform for streamlined ordering by hospitals and health systems. Labcorp also rolled out the PD-L1 IHC 22C3 pharmDx companion diagnostic for Merck's KEYTRUDA in platinum-resistant ovarian cancer nationwide and is launching the AI-powered MyLabcorp app this month. Baird raised PT to $334 from $332. Shares traded near $254.85 on May 14. Risk: payer reimbursement pressure and ramp risk in oncology specialty mix.
May 14Labcorp CEO Adam Schechter sold 5,903 shares on May 11 after Q1 beat and raised FY26 EPS guide to $17.70-$18.35Positive▶
On May 11, 2026, Labcorp CEO Adam Schechter sold 5,903 shares of LH stock. Q1 2026 revenue grew 6% YoY to $3.54B (vs $3.51B est) with adjusted EPS of $4.25 beating $4.12 consensus; FY26 adjusted EPS guidance raised to $17.70-$18.35 from prior $17.55-$18.25 and revenue guidance of $14.7-$14.8B. The company is launching MyLabcorp, an AI-powered consumer mobile app, and rolled out nationwide sales of Agilent PD-L1 IHC 22C3 PharmDx companion diagnostic for ovarian cancer. Baird raised PT to $334 (May 1); Evercore ISI maintained Buy. Stock around $258 on May 9. Risk: insider selling and biopharma research budget cycles.
May 13Labcorp announced May 12 expanded Epic collaboration making full test menu available through Aura unified ordering platform; Baird raised PT to $334 from $332.Positive▶
On May 12, 2026, Labcorp announced an expanded collaboration with Epic, with Labcorp's full test menu now available through Aura, Epic's unified platform for ordering and receiving lab results. On May 1, Baird raised the price target to $334 from $332, and Evercore ISI maintained its Buy rating. Q1 2026 (reported April 30) delivered revenue of $3.54B (+5.8% YoY) and adjusted EPS of $4.25. The company raised FY26 adjusted EPS guidance to $17.70-$18.35 from $17.55-$18.25. Labcorp stock closed at $255.08 on May 11.
May 12Labcorp raised FY26 adjusted EPS guidance to $17.70-$18.35 after Q1 revenue of $3.54B (+6%) beat consensus; launched MyLabcorp AI-powered mobile app and Baird raised PT to $334 from $332 on May 1.Positive▶
Labcorp reported Q1 2026 revenue of $3.54B (+6% YoY) beating $3.51B consensus, with adjusted EPS of $4.25 reflecting double-digit growth. The company raised full-year 2026 adjusted EPS guidance to $17.70-$18.35 (midpoint ~10% growth) and free cash flow guidance to $1.24-$1.36B. Labcorp launched MyLabcorp, an AI-powered mobile app for test results and health data, in May. Growth came from specialty testing in neurology and oncology, plus acquired lab integration. CEO Adam Schechter highlighted Children's Hospital of Philadelphia collaboration and new Alzheimer's/liquid biopsy diagnostics. Baird raised PT to $334 (from $332) and Evercore ISI maintained Buy on May 1.
Key Fundamentals
RSI (14-Day)
52-Week Range
Moving Averages
Price below 200d MA — bearish structure.